Cytokine modulators may be novel drugs for MDD in chronically inflamed subjects, as anti-TNF-α such as infliximab improved MDD symptoms in patients with increased CRP levels (Raison et al., 2013). The gene discussed is CRP; the disease is major depressive disorder.